Skip to content
Baker Capital StrategiesMARKETS. FILINGS. PERSPECTIVE.
Powered by THEMA

BAKER CAPITAL STRATEGIES

Get the free weekly BCS email.

Selected company filings and market updates, delivered by email. Your first report will follow soon.

  • Your weekly BCS reportMarket updates and links to filings you can explore.
  • THEMA at launchWe’ll send directions for setting up your filing alerts when THEMA officially opens.

One signup for the weekly email and your free THEMA Basic account at launch.

Already registered or a CSW member?Log in to THEMA →

At least 8 characters. This also creates your free THEMA account for launch.

You’re signing up for the weekly BCS email and THEMA launch/setup updates. Unsubscribe using the link in any email. Privacy policy · Terms

BCS

Beneficial Ownership Report · SCHEDULE 13D

Aktis Oncology, Inc.

Beneficial Ownership Report

Filed Jan 20, 2026Accepted Jan 20, 2026, 2:01 PM ESTFiling CIK 2035832Accession 0000935836-26-000046
Share

Structured filing — SCHEDULE 13D

primary_doc.xml

Open full document ↗

Subject company

Company
Aktis Oncology, Inc.
Company CIK
0002035832
Street
17 DRYDOCK AVENUE
Street (continued)
SUITE #17-401
City
BOSTON
State / country code
MA
Postal code
02210

Statement details

Security class
Common Stock
Event date
01/12/2026
Previously filed indication
false

Authorized notification person 1

Name
Anthony J. Caldwell, Esq.
Phone
(415) 421-6500
Street
Shartsis Friese LLP
Street (continued)
425 Market Street, 11th Floor
City
San Francisco
State / country code
CA
Postal code
94105

Reporting person 1

Name
EcoR1 Capital, LLC
Reporting person CIK
0001587114
No reporting person CIK indication
N
Citizenship / organization
DE
Reporting person type
IA · OO
Group designation
b
Source of funds code
AF
Legal proceedings indication
N
Aggregate amount owned
4,824,469.00
Percent of class
9.1
Sole voting power
0.00
Shared voting power
4,824,469.00
Sole dispositive power
0.00
Shared dispositive power
4,824,469.00
Aggregate excludes certain shares
N
Comments
Percentage calculated based on 53,296,950 shares of Common Stock outstanding following the Issuer's initial public offering, as reported in the prospectus filed by the Issuer on January 9, 2026.

Reporting person 2

Name
Oleg Nodelman
Reporting person CIK
0001454385
No reporting person CIK indication
N
Citizenship / organization
X1
Reporting person type
IN · HC
Group designation
b
Source of funds code
AF
Legal proceedings indication
N
Aggregate amount owned
4,862,335.00
Percent of class
9.1
Sole voting power
37,866.00
Shared voting power
4,824,469.00
Sole dispositive power
37,866.00
Shared dispositive power
4,824,469.00
Aggregate excludes certain shares
N
Comments
The shares reported herein include 37,866 shares of Common Stock issuable under stock options granted to Mr. Nodelman in his capacity as a director of the Issuer. 1/36th of the original number of shares subject to the option shall vest in monthly installments from January 8, 2026, subject to Mr. Nodelman's continuous service through each vesting date, inclusive. Percentage calculated based on 53,296,950 shares of Common Stock outstanding following the Issuer's initial public offering, as reported in the prospectus filed by the Issuer on January 9, 2026.

Reporting person 3

Name
EcoR1 Capital Fund Qualified, L.P.
Reporting person CIK
0001598292
No reporting person CIK indication
N
Citizenship / organization
DE
Reporting person type
PN
Group designation
b
Source of funds code
WC
Legal proceedings indication
N
Aggregate amount owned
4,348,658.00
Percent of class
8.2
Sole voting power
0.00
Shared voting power
4,348,658.00
Sole dispositive power
0.00
Shared dispositive power
4,348,658.00
Aggregate excludes certain shares
N
Comments
Percentage calculated based on 53,296,950 shares of Common Stock outstanding following the Issuer's initial public offering, as reported in the prospectus filed by the Issuer on January 9, 2026.

Item 1

Issuer

Aktis Oncology, Inc.

Security title

Common Stock

Principal address

Item 2

Citizenship

For citizenship of the reporting persons, see Item 6 of each reporting person's cover page.

Principal occupation

EcoR1 is an investment adviser to investment funds, including Qualified Fund (collectively, the "Funds"). EcoR1 is the general partner of the Funds. Mr. Nodelman is the manager and control person of EcoR1.

Filing person

The reporting persons are: EcoR1 Capital, LLC, a Delaware limited liability company ("EcoR1") EcoR1 Capital Fund Qualified, L.P., a Delaware limited partnership ("Qualified Fund") Oleg Nodelman Qualified Fund is filing this statement jointly with the other reporting persons, but not as a member of a group, and it expressly disclaims membership in a group. In addition, the filing of this Schedule 13D on behalf of Qualified Fund should not be construed as an admission that it is, and it disclaims that it is, a beneficial owner, as defined in Rule 13d-3 under the Act, of any securities covered by this Schedule 13D. Each reporting person also disclaims beneficial ownership of the securities reported herein except to the extent of that person's pecuniary interest therein.

Criminal proceedings response

During the last five years, none of the reporting persons has been convicted in a criminal proceeding (excluding traffic violations or similar misdemeanors).

Proceedings description

During the last five years, none of the reporting persons was a party to a civil proceeding of a judicial or administrative body of competent jurisdiction and as a result of such proceeding was or is subject to a judgment, decree or final order enjoining future violations of, or prohibiting or mandating activities subject to, federal or state securities laws or finding any violation with respect to such laws.

Principal business address

357 Tehama Street #3, San Francisco, CA 94103

Item 3

Source of funds

The Funds purchased 11,400,000 shares of the Issuer's Series A Redeemable Convertible Preferred Stock for an aggregate purchase price of $22,800,000, including $19,827,620 paid by Qualified Fund for 9,913,810 shares. The Funds purchased 2,500,000 shares of the Issuer's Series B Redeemable Convertible Preferred Stock for an aggregate purchase price of $10,000,000, including $9,590,000 paid by Qualified Fund for 2,397,500 shares. Immediately prior to the closing of the initial public offering of the Issuer's Common Stock on 1/12/2026, the shares of Series A Redeemable Convertible Preferred Stock and Series B Redeemable Convertible Preferred Stock held by the Funds automatically converted on a 3.8044-for-1 basis into 2,602,247 shares of the Issuer's Common Stock and 1,051,412 shares of the Issuer's Class A Common Stock. No additional consideration was paid on such conversion. In addition, certain of the Funds purchased 2,222,222 shares of Common Stock in the Issuer's initial public offering on 1/12/2026 for an aggregate purchase price of $39,999,996. Qualified Fund purchased 2,077,779 of these shares for a purchase price of $37,400,022. The foregoing purchases of securities were all made from the Funds' working capital. On 1/8/2026, Mr. Nodelman received a grant of options to acquire 37,866 shares of the Issuer's Common Stock for his service on the Issuer's board of directors.

Item 4

Purpose of transaction

Oleg Nodelman, the manager of EcoR1, is a member of the Issuer's board of directors. The reporting persons acquired securities of the Issuer for investment purposes based on their belief that the Issuer's securities represented an attractive investment opportunity. The reporting persons will routinely monitor the Issuer regarding a wide variety of factors that affect their investment considerations, including, current and anticipated future trading prices of the Common Stock and other securities, the Issuer's operations, assets, prospects, financial position, and business development, Issuer's management, Issuer-related competitive and strategic matters, general economic, financial market and industry conditions, and other investment considerations. Depending on their evaluation of various factors, the reporting persons may take such actions regarding their holdings of the Issuer's securities as they deem appropriate in light of circumstances existing from time to time. Such actions may include purchasing additional Common Stock in the open market, through privately negotiated transactions with third parties or otherwise, converting shares of Class A Common Stock into shares of Common Stock and selling at any time, in the open market, through privately negotiated transactions with third parties or otherwise, all or part of the Common Stock or other securities that they now own or hereafter acquire. The reporting persons also may from time to time enter into or unwind hedging or other derivative transactions with respect to the Common Stock or pledge their interests in the Common Stock and other securities to obtain liquidity. In addition, from time to time the reporting persons and their representatives and advisers may communicate with other stockholders, industry participants and other interested parties about the Issuer. The reporting persons have no present plan or proposal that relates to or would result in any of the actions specified in clauses (a) through (j) of Item 4 of Schedule 13D. However, as noted above, Mr. Nodelman serves on the Issuer's board of directors, and the reporting persons may recommend action to the Issuer's management, board of directors and stockholders. Any such actions could involve one or more of the events referred to in clauses (a) through (j) of Item 4 of Schedule 13D, including, potentially, one or more mergers, consolidations, sales or acquisitions of assets, changes in control, issuances, purchases, dispositions or pledges of securities or other changes in capitalization.

Item 5

Number of shares

(i) Sole power to vote or to direct the vote: EcoR1: 0 Oleg Nodelman: 37,866 Qualified Fund: 0 (ii) Shared power to vote or to direct the vote: EcoR1: 4,824,469 Oleg Nodelman: 4,824,469 Qualified Fund: 4,348,658 (iii) Sole power to dispose or to direct the disposition of: EcoR1: 0 Oleg Nodelman: 37,866 Qualified Fund: 0 (iv) Shared power to dispose or to direct the disposition of: EcoR1: 4,824,469 Oleg Nodelman: 4,824,469 Qualified Fund: 4,348,658

Transactions

In the 60 days preceding the date of this Schedule 13D, the reporting persons engaged in the transactions in the Issuer's Common Stock described in Item 3 above.

Other persons with an interest

Not applicable.

Date ownership ceased to exceed 5%

Not applicable.

Percentage of class

EcoR1: 4,824,469 Oleg Nodelman: 4,862,335 Qualified Fund: 4,348,658 Aggregate percentage of the class of Common Stock beneficially owned by the reporting persons: EcoR1: 9.1% Oleg Nodelman: 9.1% Qualified Fund: 8.2%

Item 6

Contracts and arrangements

EcoR1 is the investment adviser to its clients pursuant to investment management agreements or limited partnership agreements providing to EcoR1 the authority, among other things, to invest the funds of such clients in Stock, to vote and dispose of Stock and to file this statement on behalf of such clients. Pursuant to such limited partnership agreements, EcoR1 is entitled to allocations based on assets under management and realized and unrealized gains. Pursuant to such investment management agreements, EcoR1 is entitled to fees based on assets under management and realized and unrealized gains. The Funds hold the aggregate amount of 1,051,412 shares of the Issuer's Class A Common Stock. Each share of Class A Common Stock is convertible into one share of the Issuer's Common Stock at the holder's election, provided that the shares may not be converted if doing so would result in EcoR1 or any of the Funds beneficially owning more than 4.99% of the outstanding shares of Common Stock. Due to this limitation, the shares of Class A Common Stock held by the Funds are not presently convertible. The Funds are party to a Third Amended and Restated Investors' Rights Agreement, dated September 20, 2024, with the Issuer (the "Rights Agreement"). The Rights Agreement grants certain rights to the Funds, including certain demand, piggyback and Form S-3 registration rights with respect to the registrable securities held by them. The terms and provisions of the Rights Agreement are described more fully in the Issuer's Registration Statement on Form S-1/A (File No. 333-292283) declared effective by the Commission on January 7, 2026 (the "Registration Statement"), and the above summary is qualified by reference to such description and the full text of the Rights Agreement, which is filed as Exhibit 99.2 to this Schedule 13D and is incorporated herein by reference. In connection with the initial public offering of the Issuer's Common Stock, each of the Funds and Mr. Nodelman has entered into lock-up agreements, pursuant to which each of them have agreed, subject to certain exceptions, not to sell, transfer or otherwise convey any of the Issuer's securities held by the Funds for 180 days following the date of the offering. The terms and provisions of such lock-up agreements are described more fully in the Registration Statement, and the above summary is qualified by reference to such description and the full text of the lock-up agreement, a form of which is filed as Exhibit 99.3 to this Schedule 13D and is incorporated herein by reference. Mr. Nodelman, in his capacity as a director, may be entitled to receive cash compensation and equity compensation, including stock option or other equity awards, pursuant to the Issuer's 2026 Equity Incentive Plan (the "2026 Plan"), and the Issuer's non-employee director compensation policy (the "Compensation Plan"). The terms and provisions of the 2026 Plan and the Compensation Plan are described in the Registration Statement, and the above summary is qualified by reference to such description and the full text of which is filed as Exhibit 99.4 and Exhibit 99.5 to this Schedule 13D and are incorporated herein by reference. In addition, the Issuer has entered into an indemnification agreement with each of its directors and executive officers, including Mr. Nodelman. The indemnification agreement requires the Issuer, among other things, to indemnify Mr. Nodelman for some expenses, including attorneys' fees, judgments, fines and settlement amounts incurred by him in any action or proceeding arising out of his services as director. The terms and provisions of the indemnification agreement are described more fully in the Registration Statement, and the above summary is qualified by reference to such description and the full text of the Registration Statement, which is filed as Exhibit 99.6 to this Schedule 13D and is incorporated herein by reference.

Item 7

Filed exhibits

Exhibit 99.1: Agreement Regarding Joint Filing of Statement on Schedule 13D or 13G. Exhibit 99.2: Third Amended and Restated Investors' Rights Agreement, dated as of September 20, 2024 (filed as Exhibit 4.1 to the Issuer's Registration Statement on Form S-1/A as filed with the Commission on January 7, 2026 (SEC File No. 333-292283) and incorporated herein by reference). Exhibit 99.3: Form of Lock-Up Agreement for certain directors, officers and other stockholders of the Issuer (filed as part of Exhibit 1.1 to the Issuer's Registration Statement on Form S-1/A as filed with the Commission on January 7, 2026 (SEC File No. 333-292283) and incorporated herein by reference). Exhibit 99.4: 2026 Equity Incentive Plan, as amended, and associated forms (filed as Exhibit 10.2 to the Issuer's Registration Statement on Form S-1/A as filed with the Commission on January 7, 2026 (SEC File No. 333-292283) and incorporated herein by reference). Exhibit 99.5: Non-Employee Director Compensation Policy, as amended, and associated forms (filed as Exhibit 10.5 to the Issuer's Registration Statement on Form S-1/A as filed with the Commisson on January 7, 2026 (SEC File No. 333-292283) and incorporated herein by reference). Exhibit 99.6: Form of Indemnification Agreement (filed as Exhibit 10.6 to the Issuer's Registration Statement on Form S-1/A as filed with the Commission on January 7, 2026 (SEC File No. 333-292283) and incorporated herein by reference).

Signature 1

Reporting person
EcoR1 Capital, LLC
Signed
/s/ Oleg Nodelman
Title
Manager
Date
01/20/2026

Signature 2

Reporting person
Oleg Nodelman
Signed
/s/ Oleg Nodelman
Title
Reporting person
Date
01/20/2026

Signature 3

Reporting person
EcoR1 Capital Fund Qualified, L.P.
Signed
/s/ Oleg Nodelman
Title
Manager of the General Partner, EcoR1 Capital, LLC
Date
01/20/2026

Filed exhibits

Company context

We are a clinical-stage oncology company focused on expanding the breakthrough potential of targeted radiopharmaceuticals to large patient populations, including those not addressed by existing platform technologies. The field of targeted radiopharmaceuticals is currently led by two marketed products that illustrated transformative survival outcomes and quality of life benefits can be conferred by delivering radioisotopes to solid tumors. These leading products, which target prostate specific membrane antigen or somatostatin-2 receptor, are each currently approved in only one tumor type yet have seen considerable commercial uptake and have become fundamental pillars of cancer treatment. Despite these advances, we believe that the field of radiopharmaceuticals is still in its infancy, with many emerging companies still primarily focused on these same two targets. In contrast, we see a significant opportunity to broaden the cancer patient populations benefiting from targeted radiopharmaceuticals by developing next-generation technologies that expand the scope of tumor targets for which it is possible to safely deliver a powerful payload of an alpha-emitting radioisotope. To ensure patient demand is reliably met, we are also establishing efficient end-to-end supply, with a combination of critical internal capabilities paired with established external vendors. Through these efforts, we seek to maximize clinical utility across multiple indications in multiple tumor types, and to e

Current securities

Historical securities (1)

Recent company filings

  1. 144 filingSep 23, 2026
  2. 10-Q filingAug 13, 2026
  3. Results of Operations and Financial ConditionAug 13, 2026
  4. 144 filingJul 20, 2026
  5. 144 filingJul 17, 2026

Privacy choices

BCS measures page use with Google Analytics using regional consent settings. You can change your preference here. Charts and market data remain available.

Essential functions — always available. Security, navigation, registration and remembering these choices.

Audience analytics

Analytics cookies are off by default for visitors Google identifies in the EEA, UK or Switzerland until allowed. Limited measurement without analytics cookies may still occur under those regional defaults.

TradingView charts, quotes and the economic calendar load automatically as page content. TradingView receives network and browser information and may collect its own usage analytics. This choice controls BCS’s Google Analytics only.

Google advertising is not enabled. Direct sponsor links do not load advertising trackers on BCS.

Turning analytics off stops future Google Analytics activity here. It does not erase information already received by the provider. Read the privacy policy.